Abstract library

121 results for "Khan".
#826 Correlation of Serum Chromogranin A Change with Radiographic Response in Patients with Non-Functioning Advanced Neuroendocrine Tumors
Introduction: Numerous studies have suggested that CgA determination may be useful for the diagnosis and follow-up of neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Yuejuan Cheng
Authors: Cheng Y, Sun Z, Bai C, Ying H, ...
#2035 Prevalence of Carcinoid Syndrome (CS) in the European Union (EU)
Introduction: Epidemiologic data on CS, which typically occurs in patients with advanced midgut or lung neuroendocrine tumors (NET), are scarce and appear to be heterogeneous across countries.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MSc Julie Mouchet
#2039 Short-Term Change in Symptoms and Adverse Events Evaluation after PRRT – First Experience after 56 Patients
Introduction: From March 2016, patients with M+ NET are treated with PRRT at the Netherlands Cancer Institute.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MSc Daphne Huizing
#2190 A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors
Introduction: Retrospective studies showed that changes in plasma chromogranin A (CgA) might predict change in tumor burden in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Gitte Dam
Keywords: gep-net, ct, cga, correlation
#809 Serum Chromogranin A is a Predictor for Liver Metastatic Tumor Burden and Therapeutic Response in Advanced Non-Functional Pancreatic Neuroendocrine Tumors
Introduction: The relationship between CgA level and liver metastatic (LM) tumor burden as well as therapeutic response is not well-established.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: M.D. Xu Han
Authors: Zhang C, Han X, Tang M, Ji Y, ...
Keywords: CgA NF-PNETs LM
#138 The use of F-18-FDG-PET for patients with neuroendocrine tumors
Introduction: Neoplastic tissue exhibits high glucose utilization, which can be imaged by 18F-Fluorodeoxyglucose-positron emission tomography (FDG-PET). Whether FDG-PET is useful for neuroendocrine (NE) tumors, however, is questionable, due to the slow growth rate often observed in these tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: M.Sc. Tina Binderup
#153 Antibody formation against somatostatin analogues with altered biodistribution and dosimetry: a case with implications for PRRT
Introduction: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) has emerged as a powerful palliative therapy. I.v. administration of radiolabeled (e.g. Yttrium-90) somatostatin analogues (SA) results in high-dose local irradiation of all tumor sites. The radiolabelled SA accumulates in the tumors through receptor-mediated internalization depending on the expression of somatostatin receptors and the pharmacokinetics of the radiolabelled SA.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Sofie Van Binnebeek
#192 Successfull Endoscopic Ultrasound-Guided Alcoholic Ablation of Insulinoma
Introduction: Insulinomas are rare endocrine tumors. The golden treatment is surgical resection. EUS-guided alcohol ablation is a new promising method to treat those patients who are not surgical candidates.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Christina Schnack
Authors: schnack C, Hansen C, Nielsen H, ...
#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: M.D. Ingrid Holst Olsen
#427 Gastric Carcinoids: Prevalence in Europe and USA, and Rationale for Treatment with YF476, a Gastrin Receptor Antagonist
Introduction: Gastric carcinoids (GC) are tumors arising from enterochromaffin-like (ECL) cells in the gastric mucosa. Most are caused by hypergastrinaemia, which stimulates ECL-cell growth. YF476 is a potent, selective and orally active gastrin receptor antagonist in humans in vitro and in vivo. YF476 prevented and caused shrinkage of GC in animal models of the condition.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Malcolm Boyce
Authors: Boyce M, ...